---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-053294"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:29:29.873529+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology appoints Brian Piper as EVP, CFO; base salary $515K, option grant of 900K shares

## Summary
- Brian Piper appointed EVP, CFO and Treasurer effective February 17, 2026; replaces Steven Harr as acting principal financial officer.
- Annual base salary of $515,000 with target bonus of 40% of base salary.
- Granted option to purchase 900,000 shares (25% vest year 1, then monthly) and 200,000 RSUs (4-yr annual vest).
- Piper previously CFO at Scorpion Therapeutics, Antares Therapeutics, and Prelude Therapeutics; over 25 years biopharma finance experience.
- Company expects initial clinical data for SC451 (type 1 diabetes) and SG293 (B-cell disease) in next 12-18 months.

## SEC filing metadata
- accession: 0001193125-26-053294
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312526053294/0001193125-26-053294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312526053294/sana-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-053294
- JSON: https://secwatch.observer/filing/0001193125-26-053294.json
- Plain text: https://secwatch.observer/filing/0001193125-26-053294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.